INC Research, a therapeutically-focused contract research
organization with a trusted process for delivering reliable results,
announced today the opening of a new office in Zurich, Switzerland.
Located at Flora-Str. 44, CH-8032, Zurich, the facility will serve as
an additional base of clinical operations in Europe and allow for
substantial future expansion in the region going forward.
Dr. Hans Joerg Moebius, senior vice president of the CNS practice
for INC Research, will oversee the Zurich office, from where he will
manage the overall strategic development and ongoing operations of the
European CNS staff and business. The Zurich location will also be a
strong base of operations for the company's oncology, infectious
disease and pediatrics business units.
Kelvin Logan, PhD, President of INC Research Europe, stated, "Our
international base of operations has expanded strategically this last
year, with the addition of several new offices in Central, Eastern and
Western Europe. Our Zurich office brings us to 16 offices in 14
countries across Europe. With strong leadership such as that provided
by Dr. Moebius in Zurich, we will continue to expand our corporate
footprint around the globe in areas that provide access to sites and
patients critical to supporting our pharma and biotech customers."
"Zurich is an epicenter of European biotechnology and
pharmaceutical innovation. INC Research saw the need for a trusted,
experienced contract research organization with top clinical personnel
and data analysts here to meet the growing demands of these
businesses," said Dr. Moebius. "This new location will allow INC
Research to further solidify and expand our presence within the world
CRO market."
The Zurich office can be reached at +41-44-383-5878.
About INC Research(R)
INC Research is a therapeutically focused contract research
organization with an unrivaled reputation for conducting global
clinical development programs of the highest integrity. Pharmaceutical
and biotechnology companies look to INC Research for a complete range
of customized Phase 1 - Phase 4 programs in therapeutic areas of
specialty, and in innovative pediatric trials. Our "Trusted
Process(TM)" methodology and therapeutic foresight leads our customers
to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, North Carolina,
and in 22 locations in 35 countries worldwide. For more information,
please visit our website at www.incresearch.com.
